Republica Moldova -
română -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
agisept classical 1,2 mg/0,6 mg pastile
agio pharmaceuticals ltd - spiritul dichlorbenzylicus + amylmetacrezolum - pastile - 1,2 mg/0,6 mg
Republica Moldova -
română -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
agisept menthol - eucalyptus 1,2 mg/0,6 mg pastile
agio pharmaceuticals ltd - spiritul dichlorbenzylicus + amylmetacrezolum - pastile - 1,2 mg/0,6 mg
Republica Moldova -
română -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
agisept honey-lemon 1,2 mg/0,6 mg pastile
agio pharmaceuticals ltd - spiritul dichlorbenzylicus + amylmetacrezolum - pastile - 1,2 mg/0,6 mg
Uniunea Europeană -
română -
EMA (European Medicines Agency)
tysabri
biogen netherlands b.v. - natalizumab - scleroză multiplă - imunosupresoare selective - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.